Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials

Borchmann, Sven; Müller, Horst; Hude, Ida; Fuchs, Michael; Borchmann, Peter; Engert, Andreas

doi:10.1093/annonc/mdz168

Cited by 24 publications

(28 citation statements)

References 27 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of development of VTE was highest in the first year (47 events/1000 patient-years) and fell sharply over time (7 events/1000 patient-years in the second follow-up year) [27]. These IR are similar to another population-based study from Denmark (Lund) [28] or from pooled analyses of clinical trials [9,22]. IR reported from single-center studies tended to be higher, ranging from 10-15% (Table 1) [6,8,12,13,[15][16][17][19][20][21].…”

Section: Epidemiologysupporting

confidence: 73%

Section: Methodsmentioning

confidence: 99%

“…and V.D.S.). Of the 25 studies included, 12 studies were retrospective single-center studies [7,8,[10][11][12][13][14][15][16][17][18][19], two studies were retrospective multicenter trials [20,21], two pooled analysis of clinical trials [9,22], two meta-analyses [23,24], two analyses of patients [25,26] and three analyses of population-based registries [27][28][29], and two prospective single-center studies [6,30] (Table 1). Patients included into these studies were identified by institutional databases in 14 studies [7,8,[10][11][12][13][14][15][16][18][19][20][21]30], by the local hospital discharge registry in one study [17], by cancer registries in four studies (California Cancer Registry [27], VA Cancer registry [25], Swedish cancer registry [29], Danish lymphoma database [28]), by clinical trial registries in five ...…”

Section: Methodsmentioning

confidence: 99%

“…The composition of patient cohorts varied widely both in terms of numbers, ranging from 42 to 16,755 patients, and in types of histologies included (Table 1). Ten studies analyzed the VTE risk in patient cohorts with a single histology [6,9,10,[16][17][18][19][20][21]29]. Other cohort restrictions were, for example, the use of almost only male patients in the VA Cancer registry [25], only patients receiving at least one chemotherapy cycle [15], patients who had at least one hospital admission [8], or patients who had at least one serum sample available [6].…”

Section: Methodsmentioning

confidence: 99%

“…Only a minority of patients (12.6%) in this study had lymphoma. Several studies indicate that risk factors for VTE in patients with lymphoma are different from risk factors in patients with solid tumors [6][7][8][9]. To provide more information on the VTE risk in patients with lymphoma, we conducted a systematic review of the literature to determine the incidence of VTE in patients with lymphoproliferative disease and to identify disease and patient characteristics associated with the greatest risk for VTE.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis

Hohaus

Bartolomei

Cuccaro

et al. 2020

Cancers

View full text Add to dashboard Cite

Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism (VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the literature of the last 20 years for reports identifying these risk factors in cohorts consisting exclusively of lymphoma patients. We selected 25 publications. The most frequent studies were analyses of retrospective single-center cohorts. We also included two reports of pooled analyses of clinical trials, two meta-analyses, two analyses of patient registries, and three analyses of population-based databases. The VTE risk is the highest upfront during the first two months after lymphoma diagnosis and decreases over time. This upfront risk may be related to tumor burden and the start of chemotherapy as contributing factors. Factors consistently reported as VTE risk factors are aggressive histology, a performance status ECOG ≥ 2 leading to increased immobility, more extensive disease, and localization to particular sites, such as central nervous system (CNS) and mediastinal mass. Association between laboratory values that are part of risk assessment models in solid tumors and VTE risk in lymphomas are very inconsistent. Recently, VTE risk scores for lymphoma were developed that need further validation, before they can be used for risk stratification and primary prophylaxis. Knowledge of VTE risk factors in lymphomas may help in the evaluation of the individual risk-benefit ratio of prophylaxis and help to design prospective studies on primary prophylaxis in lymphoma.

show abstract

Section: Epidemiologysupporting

confidence: 73%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis

Hohaus

Bartolomei

Cuccaro

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer

Cavalcanti

2022

Chemotherapy Protocols and Infusion Sequence

View full text Add to dashboard Cite

Central venous catheter–associated complications in pediatric patients diagnosed with Hodgkin lymphoma: implications for catheter choice

Bosch

Spijkerman

Wijnen

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Purpose The purpose of this study was to determine the most optimal central venous catheter (CVC) for pediatric patients with Hodgkin lymphoma (HL) in terms of complications. Methods A retrospective study including patients diagnosed with HL from 2015 to 2021 at the Princess Máxima Center was performed. Patients were followed from CVC insertion until removal or 06–2021, whichever came first. The primary outcome was the CVC-related complication incidence rate (IR) per 1000 CVC-days. Furthermore, the incidence rate ratio (IRR) was calculated by comparing complication IRs between peripherally inserted central catheters (PICC) and totally implantable venous access ports (TIVAP). Additionally, risk factors for central venous thrombosis (CVT) were identified. Results A total of 98 patients were included. The most frequently observed complications were local irritation/infections (18%; IR 0.93), malfunctions (15%; IR 0.88), and CVC-related CVTs (10%; IR 0.52). Single lumen PICCs were associated with a higher risk of complications (49% vs. 26%; IRR 5.12, CI95% 2.76–9.50), severe complications (19% vs. 7%; IRR 11.96, CI95% 2.68–53.42), and early removal (18% vs. 7%; IRR 9.96, CI95% 2.18–45.47). A single lumen PICC was identified as a risk factor for CVC-related CVT when compared to TIVAPs (12% vs. 7%, IRR 6.98, CI95% 1.45–33.57). Conclusion The insertion of a TIVAP rather than a PICC should be recommended for pediatric patients with HL, especially in the presence of CVT-related risk factors. Future trials should evaluate the efficacy and safety of direct oral anticoagulants for the primary prevention of CVT in pediatric patients with a PICC and other CVT-related risk factors.

show abstract

Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials

Cited by 24 publications

References 27 publications

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis

Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer

Central venous catheter–associated complications in pediatric patients diagnosed with Hodgkin lymphoma: implications for catheter choice

Contact Info

Product

Resources

About